Nuvectis Pharma (NVCT) Operating Expenses (2021 - 2026)

Nuvectis Pharma has disclosed Operating Expenses across 6 years of filings, most recently posting $6.3 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $6.3 million, up 12.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.3 million (up 34.48% YoY), and the FY2025 annual result was $28.0 million, up 38.74% from the prior year.
• Operating Expenses came in at $6.3 million for Q1 2026 at Nuvectis Pharma, down from $7.6 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $7.8 million in Q3 2025 to a low of $2.0 million in Q1 2022.
• The 5-year median for Operating Expenses is $5.9 million (2022), against an average of $5.6 million.
• Peak annual rise in Operating Expenses reached 8617.39% in 2022, while the deepest fall reached 39.83% in 2022.
• Nuvectis Pharma's Operating Expenses stood at $6.8 million in 2022, then gained by 1.3% to $6.9 million in 2023, then decreased by 6.07% to $6.4 million in 2024, then gained by 18.11% to $7.6 million in 2025, then retreated by 17.82% to $6.3 million in 2026.
• The last three Operating Expenses figures came in at $6.3 million (Q1 2026), $7.6 million (Q4 2025), and $7.8 million (Q3 2025), per Business Quant data.